For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love

This article was originally published in The Pink Sheet Daily

14 Sep 2010
News

The Pink Sheet Daily pinkeditor@informa.com

Executive Summary

Underreporting of adverse events may be a Russian "cultural norm," the agency says in a briefing document released in advance of an advisory panel review of Alkermes' Vivitrol (naltrexone) for opioid dependence.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Regions
Europe

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Europe

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS071166

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS071166

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love

News

Executive Summary

Related Content

Opioid Addiction Indication Could Offer Fix For Alkermes' Troubled Vivitrol

Alkermes To Fly Solo On Vivitrol After Cephalon’s Departure

Alkermes To Fly Solo On Vivitrol After Cephalon’s Departure

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert